Tags

Type your tag names separated by a space and hit enter

Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine.
Clin Pharmacol Ther. 1977 Jun; 21(6):731-5.CP

Abstract

The effect of cholestyramine (12 gm/day divided into 3 doses) on the pharmacokinetics and pharmacodynamics of a single intravenouse dose (30 mg) of phenprocoumon was studied in 6 normal subjects. Cholestyramine treatment led to an increase in the rate of elimination of phenprocoumon in all. Total clearance increased 1.5- to 2-fold. The total anticoagulant effect per dose was considerably reduced during treatment with cholestyramine. Binding studies in vitro showed that phenprocoumon is strongly bound to cholestyramine and that at a given cholestyramine concentration the percentage of phenprocoumon bound remained constant over a large concentration range of phenprocoumon. The results suggest that phenprocoumon undergoes extensive enterohepatic recycling in man which can be effectively interrupted by cholestyramine.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

862312

Citation

Meinertz, T, et al. "Interruption of the Enterohepatic Circulation of Phenprocoumon By Cholestyramine." Clinical Pharmacology and Therapeutics, vol. 21, no. 6, 1977, pp. 731-5.
Meinertz T, Gilfrich HJ, Groth U, et al. Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine. Clin Pharmacol Ther. 1977;21(6):731-5.
Meinertz, T., Gilfrich, H. J., Groth, U., Jonen, H. G., & Jähnchen, E. (1977). Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine. Clinical Pharmacology and Therapeutics, 21(6), 731-5.
Meinertz T, et al. Interruption of the Enterohepatic Circulation of Phenprocoumon By Cholestyramine. Clin Pharmacol Ther. 1977;21(6):731-5. PubMed PMID: 862312.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine. AU - Meinertz,T, AU - Gilfrich,H J, AU - Groth,U, AU - Jonen,H G, AU - Jähnchen,E, PY - 1977/6/1/pubmed PY - 1977/6/1/medline PY - 1977/6/1/entrez SP - 731 EP - 5 JF - Clinical pharmacology and therapeutics JO - Clin Pharmacol Ther VL - 21 IS - 6 N2 - The effect of cholestyramine (12 gm/day divided into 3 doses) on the pharmacokinetics and pharmacodynamics of a single intravenouse dose (30 mg) of phenprocoumon was studied in 6 normal subjects. Cholestyramine treatment led to an increase in the rate of elimination of phenprocoumon in all. Total clearance increased 1.5- to 2-fold. The total anticoagulant effect per dose was considerably reduced during treatment with cholestyramine. Binding studies in vitro showed that phenprocoumon is strongly bound to cholestyramine and that at a given cholestyramine concentration the percentage of phenprocoumon bound remained constant over a large concentration range of phenprocoumon. The results suggest that phenprocoumon undergoes extensive enterohepatic recycling in man which can be effectively interrupted by cholestyramine. SN - 0009-9236 UR - https://www.unboundmedicine.com/medline/citation/862312/Interruption_of_the_enterohepatic_circulation_of_phenprocoumon_by_cholestyramine_ DB - PRIME DP - Unbound Medicine ER -